BIG
CTMX icon

Brooklyn Investment Group’s CytomX Therapeutics CTMX Stock Holding History

Brooklyn Investment Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$261K Sell
55,478
-5,996
-10% -$30.4K 0.01% 1520
2025
Q4 		$258K Buy
+61,474
New +$234K 0.01% 1176

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Brooklyn Investment Group's CTMX Position: Q1 2026 in Review

Brooklyn Investment Group reduced its CytomX Therapeutics (CTMX) stake by 9.8% in Q1 2026, selling an estimated $30.4K and leaving 55,478 shares worth $261K. The position accounts for 0.01% of the portfolio, ranked #1520.

Brooklyn Investment Group first reported a position in CTMX in Q4 2025 and has held it in 2 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Brooklyn Investment Group held 55,478 shares of CytomX Therapeutics worth $261K as of Q1 2026.
  • Brooklyn Investment Group sold 5,996 CytomX Therapeutics shares in Q1 2026, an estimated $30.4K.
  • CytomX Therapeutics made up 0.01% of Brooklyn Investment Group's portfolio in Q1 2026, its #1520 holding.
  • Brooklyn Investment Group first reported a position in CytomX Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.